DOCSLIB.ORG

Effectiveness and Tolerability of Short Course Co-Trimoxazole, Norfloxacin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effectiveness and Tolerability of Short Course Co-Trimoxazole, Norfloxacin Le Infezioni in Medicina, n. 2, 155-160, 2015 ARTICOLO ORIGINALE / ORIGINAL ARTICLE 155 Effectiveness and tolerability of short course co-trimoxazole, norfloxacin and levofloxacin in bacteriological cure of uncomplicated urinary tract infection in outpatient setting. An open label, parallel group, randomized controlled trial Studio randomizzato, controllato, in aperto e a gruppi paralleli, sull’efficacia e la tollerabilità di un ciclo breve di cotrimossazolo, norfloxacina e levofloxacina nella guarigione microbiologica delle infezioni comunitarie, non complicate, delle vie urinarie Arpit Vallabhbhai Vachhani1, Manish Barvaliya1, Viren Naik1, Pramod Jha2, Chandrabhanu Tripathi1 1Department of Pharmacology, Government Medical College, Gujarat, India; 2Department of Medicine, Government Medical College, Gujarat, India n INTRODUCTION bacterial culture and sensitivity test reports. Some studies have shown that three days treatment with rinary tract infection (UTI) is characterized antimicrobials is as effective as seven days therapy Uby the presence of >105 microorganisms per in clinical and bacteriological cure of urinary tract milliliter of urine with pus cells and red blood infection [5]. Short duration treatment leads to cells [1]. It is commonly caused by Gram negative better patient compliance, less adverse effects and organisms like Escherichia coli, Klebsiella, Proteus, cost reduction. In the present study, we evaluated Pseudomonas, Enterobacter and also less commonly effectiveness of short course treatment with three by gram positive organisms like Staphylococcus commonly prescribed antimicrobials (co-trimoxa- saprophyticus and Streptococci [2]. Empirical anti- zole, norfloxacin and levofloxacin) for treatment microbial therapy for 7-10 days is the main stay of uncomplicated urinary tract infection in a ter- treatment [3]. Co-trimoxazole, β-lactams, amino- tiary care hospital of Gujarat, India. glycosides, and fluroquinolones are the groups of antimicrobials commonly prescribed for treatment of UTI [4]. Most of the time, broad spectrum anti- n PATIENTS AND METHODS microbials are prescribed before the availability of The study protocol was approved by the Institu- tional Review Board (IRB), Government Medical Corresponding author College, Bhavnagar (IRB No. 360/2013, dated 3rd Chandrabhanu Tripathi September, 2013). This open label, randomized E-mail: [email protected] clinical trial was registered in Clinical Trial Reg- 156 A.V. Vachhani, et al. istry of India (CTRI) [Reg. No. 2014/03/006671]. Statistical analysis: Data were expressed in propor- The study was conducted at the outpatient De- tions. Chi square test was applied for comparison partment of Medicine at Sir Takhatsinhji General of bacteriological cure rate between the study Hospital, Bhavnagar, Gujarat, India. International groups. P value <0.05 was considered as statis- Conference on Harmonization and Good Clini- tically significant. All the statistical calculations cal Practice (ICH-GCP) guidelines were followed. were performed using SPSS (version 21) software Written informed consent was obtained from each (International Business Machine, IBM - America). study participant. Sample Size calculation: Overall, 150 participants Patients aged 18-65 years with symptoms of dys- were needed to achieve 80% power with α level uria or frequency/urgency of micturation, burn- of 0.05 (two tailed), if minimal expected difference ing micturation, fever and urine culture show- in bacteriological cure rate is 20%. ing >105 colony forming unit (CFU) per milliliter (CFU/ml) were included in the study. Patients with urine culture showing less than 105 CFU/ n RESULTS mL, symptoms of upper urinary tract infection, benign prostatic hypertrophy, prostatitis, recur- One hundred seventy-five out of 203 screened rent UTI or per urethral discharge were excluded symptomatic patients with uncomplicated UTI from the study. Patients having diabetes, ECG were randomized and received the assigned treat- abnormality, abnormal liver and renal labora- ment for 3 days. Flow of study participants has tory parameters, haemoglobin <8 g/dL, pregnant been shown in Figure 1. Demographic details women were also excluded from the study. At the and baseline characteristics of patients have been time of screening, blood samples were collected shown in Table 1. Overall, Escherichia coli (74.29%) for total blood count, liver and renal function test; was the most common organism isolated followed urine samples were collected for routine and mi- by Klebsiella spp (11.43%), Streptococcus spp (6.29%), croscopic examination. Staphylococcus saprophyticus (5.14%), and Pseudomo- All the screened patients were randomized. Ran- nas spp (2.86%). At the end of 3 days treatment, domization was done with random software to bacteriological cure rates were 86.2%, 87.7% and recruit patients in 1:1:1 ratio into three different 83.3% for patients receiving co-trimoxazole, nor- study groups (Group A, B and C). Randomization floxacin and levofloxacin for 3 days, respectively. was done by a person not involved in the study As per comparisons for bacteriological cure rates and randomized codes were kept in sealed enve- for an individual organism between study groups lopes and opened at the time of patient recruit- have been shown in Figure 2, there was no any ment. Group A patients received co-trimoxazole significant difference noted between the three 960 mg twice a day; Group B patients received treatment groups for bacteriological cure rate of norfloxacin 400 mg twice a day, and Group C pa- an individual organism (p>0.05). 13.6% (6/44), tients received levofloxacin 250 mg once a day for 11.1% (1/9) and 100% (1/1) patients did not re- 3 days. Patients were called for follow-up on day spond to the co-trimoxazole in whom Escherichia 4; urine was collected for culture report. Labora- coli, Klebsiella and Pseudomonas were isolated, re- tory persons from National Accreditation Board spectively. 12.2% (6/49) and 100% (1/1) patients for Testing and Calibration Laboratories (NABL) did not respond to norfloxacin against isolated of the institution were blinded for assigned treat- Escherichia coli and Pseudomonas, respectively. ment. 16.2% (6/37), 28.6% (2/7) and 28.6% (2/7) pa- Outcome measures: Effectiveness of each treatment tients did not respond to levofloxacin in whom group was evaluated by bacteriological cure rate. Escherichia coli, Klebsiella spp and Streptococcus spp Bacteriological cure rate was defined as conver- were isolated, respectively. sion of pre-treatment positive bacterial urine cul- In all treatment groups, proportions of treatment ture into negative urinary culture on day 4. The related adverse drug reactions were found to be treatment failure was defined as positive culture similar (Table 2). There were mild adverse reac- at the end of treatment period. Adverse drug re- tions reported by the patients. No any serious ad- actions were recorded at follow up visit and com- verse drug reactions were reported during the tri- pared between the treatment groups. al. Nausea (7.43%) was the most common adverse Effectiveness and tolerability of short course co-trimoxazole, norfloxacin and levofloxacin 157 drug reaction in all three treatment groups fol- norfloxacin 400 mg twice a day and levofloxacin lowed by vomiting (5.14%) and headache (1.14%). 250 mg once a day for 3 days in patients with un- complicated urinary tract infection. In the present study, Escherichia coli (74.29%) followed by Klebsi- n DISCUSSION ella spp (11.43%), Streptococcus spp (6.29%), Staph- ylococcus saprophyticus (5.14%), and Pseudomonas The present study compared the effectiveness and spp (2.86%) were responsible for causing UTI. tolerability of co-trimoxazole 960 mg twice a day, Gram negative bacteria were predominant com- Figure 1 - Flow of patients in present study [CONSORT statement]. Table 1 - Baseline characteristics of study participants. Baseline Group A Group B Group C Total characteristics co-trimoxazole norfloxacin levofloxacin N=175 N=58 N=57 N=60 Age (years) 47.68±16.09 47.75±15.66 47.38±13.09 47.93±15.66 Gender Male 25 (43.10) 16 (28.07) 24 (40) 65 (37.14) Female 33 (56.89) 41 (71.93) 36 (60) 110 (62.86) Organism isolated Escherichia coli 44 (75.86) 49 (85.96) 37 (61.67) 130 (74.29) Klebsiella spp 9 (15.52) 4 (7.018) 7 (11.67) 20 (11.43) Pseudomonas spp 1 (1.72) 1 (1.75) 3 (5.00) 5 (2.86) Staphylococcus saprophyticus 2 (3.45) 1 (1.75) 6 (10.00) 9 (5.14) Streptococcus spp 2 (3.45) 2 (3.51) 7 (11.67) 11 (6.29) Data are expressed as mean ± SD and absolute numbers. Values in parenthesis are in percentage. 158 A.V. Vachhani, et al. pared to Gram positive in causing the UTI [6-9]. day and levofloxacin 250 mg once a day for 5-10 Antimicrobial spectrum of co-trimoxazole in- days are equally effective [4]. Various clinical tri- cludes Gram negative bacilli like Escherichia coli, als showed similar effectiveness of short course Shigella, Salmonella, Proteus mirabilis as well as antimicrobial therapy (3 days) as compared to Gram positive cocci like Staphylococcus aureus standard duration of therapy (5-7 days) [10, 11]. and Streptococcus pneumoniae. Norfloxacin and In the present study, co-trimoxazole, norfloxacin levofloxacin are a first and a second genera- and levofloxacin for 3 days resulted in 86.2%, tion fluoroquinolone, respectively. While their 87.7% and 83.3% bacteriological cure rate, re- antimicrobial activity against Gram negative is spectively. Other studies have reported 55-91% equal, levofloxacin has an extended spectrum
Load more

Recommended publications
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Trend Analysis of Antibiotics Consumption Using WHO Aware Classification in Tertiary Care Hospital
    International Journal of Basic & Clinical Pharmacology Bhardwaj A et al. Int J Basic Clin Pharmacol. 2020 Nov;9(11):1675-1680 http:// www.ijbcp.com pISSN 2319-2003 | eISSN 2279-0780 DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20204493 Original Research Article Trend analysis of antibiotics consumption using WHO AWaRe classification in tertiary care hospital Ankit Bhardwaj*, Kaveri Kapoor, Vivek Singh Saraswathi institute of Medical Sciences, Pilakhuwa, Hapur, Uttar Pradesh, India Received: 21 August 2020 Accepted: 21 September 2020 *Correspondence: Dr. Ankit Bhardwaj, Email: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Aim of the study was to assess trend in antibiotics consumption pattern from 2016 to 2019 using AWaRe classification, ATC and Defined daily dose methodology (DDD) in a tertiary care hospital. Antibiotics are crucial for treating infectious diseases and have significantly improved the prognosis of patients with infectious diseases, reducing morbidity and mortality. The aim of the study is to classify the antibiotic based on WHO AWaRe classification and compare their four-year consumption trends. The study was conducted at a tertiary care center, Pilakhuwa, Hapur. Antibiotic procurement data for a period of 4 years (2016-2019) was collected from the Central medical store. Methods: This is a retrospective time series analysis of systemic antibiotics with no intervention at patient level. Antibiotic procurement was taken as proxy for consumption assuming that same has been used.
    [Show full text]
  • Pharmacology-2/ Dr
    1 Pharmacology-2/ Dr. Y. Abusamra Pharmacology-2 Quinolones, trimethoprim & sulfonamides Dr. Yousef Abdel - Kareem Abusamra Faculty of Pharmacy Philadelphia University 2 3 LEARNING OUTCOMES After completing studying this chapter, the student should be able to: Classify the drugs into subgroups such as quinolones and sulfonamides. Recognize the bacterial spectrum of all these antibiotic and antibacterial groups. Summarize the most remarkable pharmacokinetic features of these drugs. Numerate the most important side effects associated with these agents. Select the antibiotic of choice to be used in certain infections, as associated with the patient status including comorbidity, the species of bacteria causing the infection and concurrently prescribed drugs. Reason some remarkable clinical considerations related to the use or contraindication or precaution of a certain drug. Illustrate the mechanism of action of each of these drugs. • Following synthesis of na lidixic a c id in the early 1960s, continued modification of the quinolone nucleus expanded the spectrum of activity, improved pharmacokinetics, and stabilized compounds against common mechanisms of resistance. • Overuse resulted in rising rates of resistance in gram-negative and gram-positive organisms, increased frequency of Clostridium difficile infections, and identification of numerous tough adverse effects. • Consequently, these agents have been relegated to second-line options for various indications. 4 Pharmacology-2/ Dr. Y. Abusamra Only will be mentioned here 5 Pharmacology-2/ Dr. Y. Abusamra Most bacterial species maintain two distinct type II topoisomerases that assist with deoxyribonucleic acid Topoisomerases: Supercoiling Unwinding (DNA) replication: . DNA gyrase {supercoiling} and . Topoisomerase IV {Unwinding}. Following cell wall entry through porin channels, fluoroquinolones bind to these enzymes and interfere with DNA ligation.
    [Show full text]
  • < INVENTED NAME > See Annex1 Film-Coated Tablet 2. Q
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT < INVENTED NAME > see annex1 film-coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 Film-coated tablet contains 400 mg norfloxacin. Excipient with known effects Each film-coated tablet contains 0.5 mg sunset yellow (E110) and 3.36 mg sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet Round, orange film-coated tablet, with an engraved line on one side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications < INVENTED NAME > is indicated for the treatment of the following infections caused by norfloxacin-susceptible bacteria (see sections 4.2 and 5.1): Uncomplicated acute cystitis. In uncomplicated acute cystitis < INVENTED NAME > should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections. Urethritis including cases due to susceptible Neisseria gonorrhoeae Complicated urinary tract infections (except complicated pyelonephritis) Complicated acute cystitis Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 Posology and method of administration Posology The dosage depends on the susceptibility of the pathogens and severity of the disease, see recommended dosage in the table below. Susceptibility of the causative organism to the treatment should be tested (if possible), although therapy may be initiated before the results are available. In case of suspected failure of therapy, microbiological investigation for possible bacterial resistance should be undertaken.
    [Show full text]
  • Effects of Norfloxacin and Rifampicin on Growth and Streptolysin S Production in Hemolytic Streptococci
    Effects of Norfloxacin and Rifampicin on Growth and Streptolysin S Production in Hemolytic Streptococci Akira Taketo Department of Biochemistry I, Fukui Medical School, Matsuoka, Fukui 910—11, Japan and Yoriko Taketo Department of Pharmacology, School of Medicine, Kanazawa University, Kanazawa Ishikawa 920, Japan Z. Naturforsch. 40c, 647—651 (1985); received April 19/May 28, 1985 Streptolysin S, Norfloxacin, Rifampicin, Streptococcus pyogenes Norfloxacin, a nalidixic acid analogue, inhibited streptolysin S (SLS) production when added to young streptococcal culture. DNA synthesis was mainly affected, but increment of cell mass, RNA and protein was also significantly reduced in streptococci treated with norfloxacin. In stationary phase cells and in the washed resting bacteria, the toxin production was resistant to the drug. Pretreatment with norfloxacin did not abolish the cellular capacity to produce SLS. Al­ though extracellular SLS was detectable at log phase of streptococcal growth, enhanced produc­ tion of the toxin occurred upon cessation of coccal multiplication. In contrast to norfloxacin, lower concentration of rifampicin inhibited SLS production, even added at late log or early stationary phase. Roles of growth phase, medium and carrier in induction of SLS production were analyzed as well. Introduction synthesis by the carrier is deficient, although RNA or oligonucleotide added as the carrier for SLS is often Streptococcal growth and SLS production are not designated as “inducer”. affected by nalidixic acid [1], an inhibitor of DNA In order to address these questions, effects of in­ gyrase. The toxin production, which requires certain hibitors of nucleic acid synthesis have been tested, carrier substance such as RNA [2] or detergent [3], is and influences of culture conditions such as carrier insensitive to novobiocin as well [1], and possible supplementation and medium shift have been ex­ role of DNA gyrase in SLS messenger RNA syn­ amined, on macromolecular synthesis or SLS-pro- thesis remains to be elucidated.
    [Show full text]
  • Trends in Antibiotic Utilization in Eight Latin American Countries, 1997–2007
    Investigación original / Original research Trends in antibiotic utilization in eight Latin American countries, 1997–2007 Veronika J. Wirtz,1 Anahí Dreser,1 and Ralph Gonzales 2 Suggested citation Wirtz VJ, Dreser A, Gonzales R. Trends in antibiotic utilization in eight Latin American Countries, 1997–2007. Rev Panam Salud Publica. 2010;27(3):219–25. ABSTRACT Objective. To describe the trends in antibiotic utilization in eight Latin American countries between 1997–2007. Methods. We analyzed retail sales data of oral and injectable antibiotics (World Health Or- ganization (WHO) Anatomic Therapeutic Chemical (ATC) code J01) between 1997 and 2007 for Argentina, Brazil, Chile, Colombia, Mexico, Peru, Uruguay, and Venezuela. Antibiotics were aggregated and utilization was calculated for all antibiotics (J01); for macrolides, lin- cosamindes, and streptogramins (J01 F); and for quinolones (J01 M). The kilogram sales of each antibiotic were converted into defined daily dose per 1 000 inhabitants per day (DID) ac- cording to the WHO ATC classification system. We calculated the absolute change in DID and relative change expressed in percent of DID variation, using 1997 as a reference. Results. Total antibiotic utilization has increased in Peru, Venezuela, Uruguay, and Brazil, with the largest relative increases observed in Peru (5.58 DID, +70.6%) and Venezuela (4.81 DID, +43.0%). For Mexico (–2.43 DID; –15.5%) and Colombia (–4.10; –33.7%), utilization decreased. Argentina and Chile showed major reductions in antibiotic utilization during the middle of this period. In all countries, quinolone use increased, particularly sharply in Venezuela (1.86 DID, +282%). The increase in macrolide, lincosaminde, and streptogramin use was greatest in Peru (0.76 DID, +82.1%), followed by Brazil, Argentina, and Chile.
    [Show full text]
  • Disabling and Potentially Permanent Side Effects Lead to Suspension Or Restrictions of Quinolone and Fluoroquinolone Antibiotics
    11 March 2019 EMA/175398/2019 Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics On 15 November 2018, EMA finalised a review of serious, disabling and potentially permanent side effects with quinolone and fluoroquinolone antibiotics given by mouth, injection or inhalation. The review incorporated the views of patients, healthcare professionals and academics presented at EMA’s public hearing on fluoroquinolone and quinolone antibiotics in June 2018. EMA’s human medicines committee (CHMP) endorsed the recommendations of EMA’s safety committee (PRAC) and concluded that the marketing authorisation of medicines containing cinoxacin, flumequine, nalidixic acid, and pipemidic acid should be suspended. The CHMP confirmed that the use of the remaining fluoroquinolone antibiotics should be restricted. In addition, the prescribing information for healthcare professionals and information for patients will describe the disabling and potentially permanent side effects and advise patients to stop treatment with a fluoroquinolone antibiotic at the first sign of a side effect involving muscles, tendons or joints and the nervous system. Restrictions on the use of fluoroquinolone antibiotics will mean that they should not be used: to treat infections that might get better without treatment or are not severe (such as throat infections); to treat non-bacterial infections, e.g. non-bacterial (chronic) prostatitis; for preventing traveller’s diarrhoea or recurring lower urinary tract infections (urine infections that do not extend beyond the bladder); to treat mild or moderate bacterial infections unless other antibacterial medicines commonly recommended for these infections cannot be used. Importantly, fluoroquinolones should generally be avoided in patients who have previously had serious side effects with a fluoroquinolone or quinolone antibiotic.
    [Show full text]
  • First Order Derivative Spectrophotometric Method for Simultaneous Estimation of Metronidazole and Norfloxacin in Their Combined Dosage Form
    International Journal of Applied and Natural Sciences (IJANS) ISSN(P): 2319-4014; ISSN(E): 2319-4022 Vol. 2, Issue 5, Nov 2013, 21-26 © IASET FIRST ORDER DERIVATIVE SPECTROPHOTOMETRIC METHOD FOR SIMULTANEOUS ESTIMATION OF METRONIDAZOLE AND NORFLOXACIN IN THEIR COMBINED DOSAGE FORM RAJYA LAKSHMI CH1 & RAMBABU C2 1Department of Chemistry, Vishnu Institute of Technology, Bhimavaram, Andhra Pradesh, India 2Department of Chemistry, Acharya Nagarjuna University, Guntur, Andhra Pradesh, India ABSTRACT Derivative spectroscopy offers a useful approach for the analysis of drugs in mixtures. In this study First order derivative spectrophotometric method was developed for the simultaneous determination of Metronidazole (MET) and Norfloxacin (NOR) in bulk and combined tablet dosage form. The derivative spectra for both the methods were obtained in methanol and the linearity was obtained in the concentration range of 1.25 – 6.25 µg/ml for Metronidazole and 1.0 - 5.0µg/ml for Norfloxacin. The zero order spectra are obtained at wavelengths 311nm for Metronidazole and 283nm for Norfloxacin. First order derivative spectrophotometric method was based on the determination of both the drugs at their respective zero crossing point (ZCP). The determinations were made at 216 nm (ZCP of Norfloxacin) for Metronidazole and 209 nm (ZCP of Metronidazole) for Norfloxacin. The mean recovery was 99.8 and 100.7 for Metronidazole and Norfloxacin respectively. The method was found to be simple, sensitive, accurate and precise and was applicable for the simultaneous determination of Metronidazole and Norfloxacin in pharmaceutical tablet dosage form. The results of analysis have been validated statistically and by recovery studies. KEYWORDS: Metronidazole, Norfloxacin, Zero Order Spectra, First Order Spectra, Zero Crossing Point Validation INTRODUCTION Metronidazole (MET), chemically known as 2-(2-methyl-5-nitro-1H- imidazol-1-yl) ethanol (figure 1) is an antibiotic, antiprotozoal, amoebicidal, bactericidal and trichomonicidal.
    [Show full text]
  • Pharmacogenomic Associations Tables
    Pharmacogenomic Associations Tables Disclaimer: This is educational material intended for health care professionals. This list is not comprehensive for all of the drugs in the pharmacopeia but focuses on commonly used drugs with high levels of evidence that the CYPs (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5 only) and other select genes are relevant to a given drug’s metabolism. If a drug is not listed, there is not enough evidence for inclusion at this time. Other CYPs and other genes not described here may also be relevant but are out of scope for this document. This educational material is not intended to supersede the care provider’s experience and knowledge of her or his patient to establish a diagnosis or a treatment plan. All medications require careful clinical monitoring regardless of the information presented here. Table of Contents Table 1: Substrates of Cytochrome P450 (CYP) Enzymes Table 2: Inhibitors of Cytochrome P450 (CYP) Enzymes Table 3: Inducers of Cytochrome P450 (CYP) Enzymes Table 4: Alternate drugs NOT metabolized by CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 or CYP3A5 enzymes Table 5: Glucose-6-Phosphate Dehydrogenase (G6PD) Associated Drugs and Compounds Table 6: Additional Pharmacogenomic Genes & Associated Drugs Table 1: Substrates of Cytochrome P450 (CYP) Enzymes Allergy Labetalol CYP2C19 Immunosuppressives Loratadine CYP3A4 Lidocaine CYP1A2 CYP2D6 Cyclosporine CYP3A4/5 Analgesic/Anesthesiology CYP3A4/5 Sirolimus CYP3A4/5 Losartan CYP2C9 CYP3A4/5 Codeine CYP2D6 activates Tacrolimus CYP3A4/5 Lovastatin
    [Show full text]
  • Fluoroquinolone Use in Paediatrics: Focus on Safety and Place in Therapy
    18th Expert Committee on the Selection and Use of Essential Medicines (2011) Fluoroquinolone Use in Paediatrics: Focus on Safety and Place in Therapy Jennifer A. Goldman, M.D. 1,2, Gregory L. Kearns, Pharm.D., Ph.D. 1,3,4 Departments of Pediatrics 1 and Pharmacology 3, University of Missouri – Kansas City and the Divisions of Pediatric Infectious Disease 2 and Clinical Pharmacology and Medical Toxicology, 4 Children’s Mercy Hospital, Kansas City, MO, USA Commissioned work for the Guidelines Group for the Revision of the “Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children”, World Health Organization, 30-31 March 2010, Geneva, Switzerland 1 I. Introduction The first quinolone, nalidixic acid, was developed in the 1960s and was used (off- label) in pediatric therapeutics without restriction. Consequent to their broad spectrum of antimicrobial (including anti-mycobacterial) effect and perceived excellent safety profile, there was considerable hope and expectation that this class of antibiotics would find an important place in pediatric therapeutics. However, reports of quinolone-associated injury in weight bearing joints of juvenile animals resulted not only in an apparent contraindication to their use in human infants and children but also, completely derailed their formal development by pharmaceutical companies for use in pediatrics. While this situation resulted from a genuine concern for safety seemingly supported by relevant experimental findings, it served initially to remove a potentially useful
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Noroxin® (Norfloxacin)
    TABLETS NOROXIN® (NORFLOXACIN) WARNING: Fluoroquinolones, including NOROXIN®, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants (See WARNINGS). To reduce the development of drug-resistant bacteria and maintain the effectiveness of NOROXIN∗ and other antibacterial drugs, NOROXIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION NOROXIN (Norfloxacin) is a synthetic, broad-spectrum antibacterial agent for oral administration. Norfloxacin, a fluoroquinolone, is 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3­ quinolinecarboxylic acid. Its empirical formula is C H FN O and the structural formula is: 16 18 3 3 Norfloxacin is a white to pale yellow crystalline powder with a molecular weight of 319.34 and a melting point of about 221°C. It is freely soluble in glacial acetic acid, and very slightly soluble in ethanol, methanol and water. NOROXIN is available in 400-mg tablets. Each tablet contains the following inactive ingredients: cellulose, croscarmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium stearate, and titanium dioxide. Norfloxacin, a fluoroquinolone, differs from non-fluorinated quinolones by having a fluorine atom at the 6 position and a piperazine moiety at the 7 position. CLINICAL PHARMACOLOGY In fasting healthy volunteers, at least 30-40% of an oral dose of NOROXIN is absorbed. Absorption is rapid following single doses of 200 mg, 400 mg and 800 mg.
    [Show full text]